If you needed proof that AI has firmly landed inside the walls of federal government, look no further than the Department of Health and Human Services. New data from the Bipartisan Policy Center reveals that AI adoption across HHS has surged dramatically in 2025, with the FDA leading the charge at a staggering 148% increase in AI utilization.
That's not a rounding error — that's a near-tripling of AI engagement at one of the most consequential regulatory agencies in the country. The FDA oversees everything from drug approvals to medical device safety, meaning AI tools embedded in those workflows carry enormous real-world implications for patients, pharmaceutical companies, and the broader healthcare economy.
What's driving the spike? Likely a combination of factors: pressure to accelerate drug review timelines, growing comfort with AI-assisted data analysis among agency staff, and a broader Biden-to-Trump transition mandate pushing federal agencies to modernize operations. The current administration has shown particular enthusiasm for deploying AI as an efficiency lever across government functions.
The industry takeaway here is significant. When a highly cautious, compliance-driven institution like the FDA adopts AI at this velocity, it sends a strong signal to the private sector — especially health tech and biotech firms — that AI-native workflows are becoming the regulatory norm, not the exception. Companies submitting applications or navigating approvals may increasingly find themselves interfacing with AI-assisted review processes on the other side of the table.
There's a flip side worth watching, though. Rapid adoption without equally rapid governance infrastructure is a known risk pattern in federal tech deployments. The critical question isn't just how much AI HHS is using — it's whether oversight frameworks are scaling at the same pace. Spoiler: they rarely do. The Bipartisan Policy Center data is a milestone marker, but the real story will be in the audits that follow.